🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. Irinotecan HCl-trihydraat Fresenius Kabi 20 mg/ml, concentraat voor oplossing voor infusie, Folinezuur Sandoz 10 mg/ml, oplossing voor injectie, Gemcitabine Sandoz 40 mg/ml, concentraat voor oplossing voor infusie, Fluorouracil Accord 50 mg/ml, oplossing voor injectie of infusie, Oxaliplatine Fresenius Kabi 5 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    non-metastatic (borderline) resectable pancreatic cancer

    phase 3 small molecule active

    1 trial

  2. Irinotecan liposome、5-Fluorouracil、Leucovorin

    Jian Li

    Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy

    phase 3 small molecule completed

    1 trial

  3. Ivabradine Anpharm 5 mg film-coated tablets, Placebo: lactose monohydrate, microcrystalline cellulose, native corn starch, colloidal anhydrous silica, maltodextrin, magnesium stearate Capsule: Beef gelatin, Glycerol, Titanium dioxide

    COLLEGIUM PHARMACEUTICAL, INC

    Myocardial Injury after Noncardiac Surgery

    phase 3 small molecule active

    1 trial

  4. Ivonescimab 10 mg/kg

    Summit Therapeutics

    Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)

    phase 3 small molecule active

    1 trial

  5. JNJ-54767414

    Janssen-Cilag International N.V.

    Precancerous form of blood cancer in the bone marrow

    phase 3 small molecule active

    1 trial

  6. JNJ-61186372, Carboplatin 10 mg/ml Intravenous Infusion, CARBOPLATIN , Pemetrexed Seacross 500 mg powder for concentrate for solution for infusion, PEMETREXED

    Janssen-Cilag International N.V.

    EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  7. JNJ-63723283, JNJ-63723283, Gemcitabina Accord 100 mg/ml concentrato per soluzione per infusione., JNJ-17000139, GEMCITABINE ACCORD 100 mg/ml, solution à diluer pour perfusion, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Gemcitabine100 mg/ml Concentrate for Solution for Infusion, Gemcitabin Accord 100 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Janssen-Cilag International N.V.

    Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder

    phase 3 small molecule active

    1 trial

  8. JNJ-73841937, Pemetrexed Seacross 500 mg powder for concentrate for solution for infusion, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung Carboplatin, JNJ-61186372, CARBOPLATIN , Carboplatin 10 mg/ml Intravenous Infusion, PEMETREXED

    Janssen-Cilag International N.V.

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  9. JNJ-77242113, Film-Coated Tablet without JNJ-77242113

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  10. JNJ-77242113, Film-Coated Tablet without JNJ-77242113, Film-Coated Tablet without Deucravacitinib, DEUCRAVACITINIB

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  11. JNJ-80202135, Placebo subcutaneous without Nipocalimab

    Janssen-Cilag International N.V.

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  12. JNJ-80202135, Placebo subcutaneous without Nipocalimab

    Janssen-Cilag International N.V.

    Sjögren's Disease

    phase 3 small molecule active

    1 trial

  13. JNJ-90301900 (NBTXR3)

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Carcinoma, Squamous Cell

    phase 3 small molecule active

    1 trial

  14. Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets, GLPG0634

    Alfasigma S.p.A.

    Polyarticular-course juvenile idiopathic arthritis

    phase 3 small molecule active

    1 trial

  15. KAI-9531, KAI-9531, Identical to kai-9531 solution for injection without active drug, KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial

  16. KARDEGIC 75 mg, poudre pour solution buvable en sachet-dose, CLOPIDOGREL, CLOPIDOGREL

    ISTA Pharma Limited

    chronically occluded coronary artery

    phase 3 small molecule active

    1 trial

  17. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ADSTILADRIN, GEMCITABINE , DOCETAXEL

    Ferring Pharmaceuticals

    High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ(CIS) with or without papillary tumours

    phase 3 small molecule active

    1 trial

  18. KEYTRUDA 25 mg/mL concentrate for solution for infusion, BI 1810631, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Boehringer Ingelheim

    non-squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  19. KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOMVANALIMAB, AB122 (Zimberelimab)

    Arcus Biosciences

    Squamous Non-small cell Lung Cancer, Non-Small Cell Lung Cancer, Non squamous Non Small Cell Lung Cancer, Lung Cancer

    phase 3 small molecule active

    1 trial

  20. KEYTRUDA 25 mg/mL concentrate for solution for infusion, IO102-IO103

    IO Biotech

    Previously untreated, unresectable, or metastatic melanoma

    phase 3 small molecule active

    1 trial

  21. KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Epacadostat, CETUXIMAB , Epacadostat, CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , FLUOROURACIL

    Incyte

    Histologically or cytologically-confirmed Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapies

    phase 3 small molecule active

    1 trial

  22. KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMBROLIZUMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Saline bag, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Ficerafusp Alfa, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Ficerafusp A

    Bicara Therapeutics

    Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

    phase 3 small molecule active

    1 trial

  23. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Livmoniplimab, Carboplatin 10 mg/ml Intravenous Infusion, Pemetrexed medac 500 mg powder for concentrate for solution for infusion, Cisplatin 1mg/ml Injection BP, Budigalimab

    AbbVie Deutschland GmbH & Co. KG

    Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  24. KEYTRUDA 25 mg/mL concentrate for solution for infusion, MYCOPHENOLATE MOFETIL, PEMETREXED, INFLIXIMAB, Rilvegostomig, PEMETREXED, CISPLATIN, CARBOPLATIN

    AstraZeneca AB

    Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources